Protein Sciences

BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS

Retrieved on: 
Monday, April 1, 2024
ISH, Protein Sciences, Education, CiteAb, ELISA, RNA, Antibody, Research, Diagnosis, ACD, Literature, Elisa's

Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.

Key Points: 
  • Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.
  • The ELISA Kit Supplier of the Year award is a testament to the depth and breadth of the R&D Systems citation database, which covers reagent data for nearly one million ELISA kit products.
  • CiteAb's Innovation Award recognizes ACD's RNAscope HiPlex12 Flex Kit, which provides greater flexibility to researchers performing in situ spatial detection of target RNA.
  • The Innovation Award given to our ACD brand underscores our Spatial Biology team's dedication to enriching our customers' experiences and prioritizing researchers' needs."

BIO-TECHNE INTEGRATES ITS MAURICE SYSTEM WITH THE THERMO SCIENTIFIC CHROMELEON CHROMATOGRAPHY DATA SYSTEM

Retrieved on: 
Tuesday, September 26, 2023
Maurice, Partnership, Ice, Chromatography, Research, Dionex, Bio-Techne, Protein Sciences, CDS, Thermo, Data analysis, Laboratory, Quality control, Compass

MINNEAPOLIS, Sept. 26, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to launch the new Maurice Chromeleon Driver Kit, which enables control of its Maurice™ instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System (CDS).

Key Points: 
  • MINNEAPOLIS, Sept. 26, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to launch the new Maurice Chromeleon Driver Kit, which enables control of its Maurice™ instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System (CDS).
  • In addition to Compass for iCE, and Waters™ Empower® CDS, scientists now can use Chromeleon CDS to analyze protein charge and size data generated from the Maurice system.
  • This exciting development adds to the broad analytical capabilities on the Maurice system to provide a streamlined data analysis and management workflow.
  • Its ability to enhance productivity, ensure data integrity, and facilitate compliance with regulatory requirements has solidified its status as a trusted chromatography data system.

Catena Biosciences Expands Executive Leadership Team, Appoints Saurabh Johri as Chief Business Officer and Rick Kendall as Chief Scientific Officer

Retrieved on: 
Wednesday, August 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Micrometer (device), Industrial engineering, Teva Pharmaceuticals, KRAS, Partnership, University, Therapy, University of California, Irvine School of Medicine, Bi-specific T-cell engager, Bachelor of Technology, Cancer, MBA, Protein Sciences, Acquisition, Motilal Nehru National Institute of Technology Allahabad, Carnegie Mellon University, Catena, Growth, Merck, Commercial, Kite Pharma, Imagination, Saurabh, PARP, Management, Fine chemical, Amgen, Bayer, Chemistry, Medicine

Catena Biosciences, Inc., a biotechnology company pioneering protein conjugation technologies for novel therapeutic development, today announced the expansion of its leadership team with two new executive appointments.

Key Points: 
  • Catena Biosciences, Inc., a biotechnology company pioneering protein conjugation technologies for novel therapeutic development, today announced the expansion of its leadership team with two new executive appointments.
  • The company has appointed Saurabh Johri as Chief Business Officer and Rick Kendall, Ph.D., as Chief Scientific Officer.
  • “Catena is in an exciting phase of growth, and we are pleased to welcome Saurabh and Rick to our growing team.
  • Saurabh joins Catena Biosciences from Bayer where he was most recently Vice President & Global Head, Oncology Strategy and Early Commercialization.

SK bioscience Appoints New Executives to Accelerate New Growth Strategies

Retrieved on: 
Friday, January 20, 2023
Global Health, Good, CGT, Hay Group Global R&D Center for Strategy Execution, University, University of California, Berkeley, INSEAD, Drug, Sanofi Pasteur, BMGF, SK, CGMP, Health, Protein Sciences, Certification, M&A, Molecular biology, COVID-19, Bachelor of Arts, Growth, Gilead Sciences, Process, Akwa Ibom State Association of Nigeria, USA Inc., R, Eastern University, Good manufacturing practice, Pennsylvania State University, Bill, Doctor of Philosophy, Fine chemical, Medical device, Biochemistry, Science

Dr. Kensinger is an expert who has been dedicated to biopharmaceutical R&D, working at global companies for more than 20 years.

Key Points: 
  • Dr. Kensinger is an expert who has been dedicated to biopharmaceutical R&D, working at global companies for more than 20 years.
  • SK bioscience additionally recruited Kenneth Lee, former Head of Commercial Division, Americas of GenScript Probio, as Vice President of Biologic Business Development Department at R&D Center in Pangyo, South Korea.
  • Mr. Lee will be in charge of developing new biopharmaceutical-driven strategies beyond the vaccine business including a Cellular & Gene Therapy (CGT) field.
  • Jaeyong Ahn, CEO of SK bioscience said, "Now is the time for advancing beyond Korea to the global market based on our accumulated capabilities.

Odyssey Therapeutics Expands Management Team with Key Appointments in Research Development and Strategy

Retrieved on: 
Wednesday, November 9, 2022
Odyssey, Pharmacology, Proteomics, University of Wisconsin–Madison School of Education, Liver, Growth, Novartis, Patient, Doctor of Philosophy, Chemistry, Decision-making, Biotechnology, Drug discovery, Harvard University, Hematology, University, AROS Research Operating System, Merck, View, Protein Sciences, Kidney, Efficiency, Degenerative disease, Therapy, Multimedia, Biochemistry, Time, Pharmaceutical industry

BOSTON, Nov. 9, 2022 /PRNewswire/ -- Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced the appointment of Jeff Hermes, Ph.D., as Executive Vice President of Enabling Sciences and promotion of Natalie Dales, Ph.D., to the newly created position of Chief of Research Operations and Portfolio Strategy. In these roles, Dr. Hermes will oversee capability development and implementation for Odyssey's platform approaches and technologies, and Dr. Dales will drive scientific strategy and facilitate collaboration across the organization.

Key Points: 
  • In these roles, Dr. Hermes will oversee capability development and implementation for Odyssey's platform approaches and technologies, and Dr. Dales will drive scientific strategy and facilitate collaboration across the organization.
  • Additionally, Natalie has played a critical role in helping shape Odyssey's research programs and strategy during her time here, and she will continue to deliver upon our portfolio strategy and streamline efforts across the company."
  • Odyssey Therapeutics is a biotechnology company focused on discovering, developing and commercializing the next generation of immunomodulators and oncology medicines.
  • For more information, please visit http://www.odysseytx.com/ and follow Odyssey Therapeutics on Twitter ( @Odyssey_Tx ) and LinkedIn .

TAE Life Sciences to Sponsor Industry Theater Session on the Future of Precision Oncology at 2022 ASTRO Annual Meeting

Retrieved on: 
Tuesday, October 18, 2022
Research, Technology, Other Technology, Clinical Trials, Biotechnology, Radiology, Pharmaceutical, Health, Science, Oncology, Neutron, News, Radiation, Neutron capture therapy of cancer, Sale, Therapy, American Society for Radiation Oncology, Neoplasm, Society, Patient, Industry, Senior, Technology, Cancer, Centre for Industry Education Collaboration, TLS, Radiation therapy, ASTRO, Protein Sciences, Economics, Health, Research, Boron, BNCT, Pharmaceutical industry, Medical imaging

TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry Education session focused on the future of biologically targeted radiotherapy at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 22-26, 2022.

Key Points: 
  • TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry Education session focused on the future of biologically targeted radiotherapy at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 22-26, 2022.
  • The Industry Theater session, A Glimpse into the Future: Biologically Targeted Radiotherapy will feature presentations by Sunil Krishnan, M.B.B.S., M.D., Professor, Radiation Oncology, UT Health Houston, Minesh P. Mehta, MD., Deputy Director & Chief of Radiation Oncology, Miami Cancer Institute and Art Raitano, Senior Director Protein Sciences, TAE Life Sciences.
  • Session Title: A Glimpse into the Future: Biologically Targeted Radiotherapy
    BNCT is one of the most exciting developments in radiation therapy, and yet it remains inadequately explored in the clinic due to technological and pharmacological limitations.
  • TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).

BIO-TECHNE INTRODUCES NEW SIMPLE PLEX AAV VIRAL TITER ASSAYS

Retrieved on: 
Tuesday, October 11, 2022
Elisa's, Bio-Techne, Faculty of Biotechnical Sciences, ELISA, NASDAQ, Quality control, Antibody, Capsid, Research, Partnership, Drug discovery, AAV, PLEX, Industry, Protein Sciences, CEO, Nature, Ella, Vaccine

MINNEAPOLIS, Oct. 11, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and PROGEN announced today the release of three new Simple Plex™ Adeno-Associated Virus (AAV) viral titer assays for intact AAV capsid quantification. Featuring best-in-class AAV reagents from PROGEN—a leader in AAV antibodies, ELISAs, and controls—the new Simple Plex AAV1, AAV6, and AAV8 viral titer assays provide users with a fully automated and quantitative method of vector analysis.

Key Points: 
  • MINNEAPOLIS, Oct. 11, 2022 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) and PROGEN announced today the release of three new Simple Plex Adeno-Associated Virus (AAV) viral titer assays for intact AAV capsid quantification.
  • Featuring best-in-class AAV reagents from PROGENa leader in AAV antibodies, ELISAs, and controlsthe new Simple Plex AAV1, AAV6, and AAV8 viral titer assays provide users with a fully automated and quantitative method of vector analysis.
  • The new Simple Plex AAV viral titer assays offer the same superior performance as the industry standard PROGEN AAV ELISAs along with the sensitivity, reproducibility, convenience and time-saving advantages inherent in the fully automated Ella immunoassay platform.
  • "The improved range of detection achievable with our Simple Plex viral titer assays is particularly useful for AAV capsid titer assessment, as samples need fewer dilutions to meet the linear range of the assay.

MAURICE FLEX™ icIEF ANALYSIS ADDS FRACTIONATION, ENABLING MASS SPEC PEAK CHARACTERIZATION

Retrieved on: 
Wednesday, September 21, 2022
Bio-Techne, IEX, National Institute of Standards and Technology, NIST, ADC, Literature, Protein Sciences, CE, Peptide, Mab, LC-MS, NASDAQ, Ion exchange, National Institute, Pharmaceutical industry, Technology

In the data presented by ProteinSimple, a Bio-Techne brand, the Maurice FlexTM instrument was used to perform icIEF analysis on the ADC's parent mAb, followed by icIEF fractionation on the same instrument.

Key Points: 
  • In the data presented by ProteinSimple, a Bio-Techne brand, the Maurice FlexTM instrument was used to perform icIEF analysis on the ADC's parent mAb, followed by icIEF fractionation on the same instrument.
  • The charge isoforms collected with the Maurice Fractionation cartridge matched the charge isoform profile of Maurice icIEF.
  • The high purity fractions (80-100%) of single-run fractionation offer a faster pathway to intact mass spectrometry analysis of the charge peaks.
  • This new capability empowers scientists to perform this analysis early in the protein therapeutic development process, enabling them to make informed decisions faster."

Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer Test

Retrieved on: 
Thursday, May 12, 2022
MBA, Disease, Bladder cancer, Food, US Foods, Patient, NASDAQ, Protein Sciences, Review, LDT, Translation, Nature, Bio-Techne, Research, FDA, Partnership, BCG, Calendar, Luminex, Cancer, Drug discovery, MD, LOS, Medical imaging, Pharmaceutical industry

MINNEAPOLIS and LOS ANGELES, May 12, 2022 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria bladder cancer diagnostic panel using xMAP Luminex technology.

Key Points: 
  • MINNEAPOLIS and LOS ANGELES, May 12, 2022 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria bladder cancer diagnostic panel using xMAP Luminex technology.
  • Oncuria is the first-of-its-kind multiplex protein-based urine test to provide early and accurate detection, therapy choice, and disease monitoring of bladder cancer.
  • Nonagen Bioscience and Bio-Techne are targeting the last quarter of calendar 2022 to make Oncuria available as an LDT.
  • The ability to quickly and accurately detect the presence of bladder cancer and monitor disease activity can help improve patient outcomes.

Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officer

Retrieved on: 
Monday, February 28, 2022
GLOBE, Therapy, HHMI, Versant, Partnering, Stanford University, Protein Sciences, University, Medicine, Antibody, Cancer, Berkeley, Protein, Lycia, SAN, Genentech, Patent, Chemistry, Doctor of Philosophy, Translational medicine, Medicinal chemistry, Medical device, Management, Research

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent appointment of Steve Staben, Ph.D., as Chief Scientific Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent appointment of Steve Staben, Ph.D., as Chief Scientific Officer.
  • Prior to joining Lycia, Dr. Staben spent over 14 years at Genentech leading drug discovery programs in oncology and immunology as well as new modality platforms.
  • Lycia is using its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins.
  • Steve models this enthusiasm and dedication, and were thrilled to have him helm our scientific organization, said Aetna Wun Trombley, Ph.D., President and Chief Executive Officer at Lycia.